Shariat SF - Search Results

1

Female gender is associated with higher risk of disease recurrence in patients with primary T1 high-grade urothelial carcinoma of the bladder.

Kluth LA, Fajkovic H, Xylinas E, Crivelli JJ, Passoni N, Rouprêt M, Becker A, Comploj E, Pycha A, Holmang S, Gupta A, Lotan Y, Karakiewicz PI, Gontero P, Chun FK, Fisch M, Scherr DS, Shariat SF. Kluth LA, et al. Among authors: shariat sf. World J Urol. 2013 Oct;31(5):1029-36. doi: 10.1007/s00345-012-0996-9. Epub 2012 Nov 30. World J Urol. 2013. PMID: 23196773

2

Prognostic value of P53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder.

Shariat SF, Weizer AZ, Green A, Laucirica R, Frolov A, Wheeler TM, Lerner SP. Shariat SF, et al. Urology. 2000 Nov 1;56(5):735-40. doi: 10.1016/s0090-4295(00)00756-1. Urology. 2000. PMID: 11068290

3

E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder.

Shariat SF, Pahlavan S, Baseman AG, Brown RM, Green AE, Wheeler TM, Lerner SP. Shariat SF, et al. Urology. 2001 Jan;57(1):60-5. doi: 10.1016/s0090-4295(00)00892-x. Urology. 2001. PMID: 11164145

4

E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup.

Byrne RR, Shariat SF, Brown R, Kattan MW, Morton RA JR, Wheeler TM, Lerner SP. Byrne RR, et al. Among authors: shariat sf. J Urol. 2001 May;165(5):1473-9. J Urol. 2001. PMID: 11342899

5

Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer.

Andrews B, Shariat SF, Kim JH, Wheeler TM, Slawin KM, Lerner SP. Andrews B, et al. Among authors: shariat sf. J Urol. 2002 Mar;167(3):1475-81. J Urol. 2002. PMID: 11832773

6

Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder.

Shariat SF, Kim JH, Ayala GE, Kho K, Wheeler TM, Lerner SP. Shariat SF, et al. J Urol. 2003 Mar;169(3):938-42. doi: 10.1097/01.ju.0000043638.89552.ed. J Urol. 2003. PMID: 12576817

7

Correlation of preoperative levels of IGF-I and IGFBP-3 with pathologic parameters and clinical outcome in patients with bladder cancer.

Shariat SF, Kim J, Nguyen C, Wheeler TM, Lerner SP, Slawin KM. Shariat SF, et al. Urology. 2003 Feb;61(2):359-64. doi: 10.1016/s0090-4295(02)02253-7. Urology. 2003. PMID: 12597948

8

Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder.

Shariat SF, Monoski MA, Andrews B, Wheeler TM, Lerner SP, Slawin KM. Shariat SF, et al. Urology. 2003 May;61(5):1053-8. doi: 10.1016/s0090-4295(02)02522-0. Urology. 2003. PMID: 12736046

9

Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder.

Shariat SF, Kim J, Raptidis G, Ayala GE, Lerner SP. Shariat SF, et al. Urology. 2003 Jun;61(6):1140-5. doi: 10.1016/s0090-4295(03)00236-x. Urology. 2003. PMID: 12809883

10

The addition of urinary urokinase-type plasminogen activator to urinary nuclear matrix protein 22 and cytology improves the detection of bladder cancer.

Shariat SF, Casella R, Monoski MA, Sulser T, Gasser TC, Lerner SP. Shariat SF, et al. J Urol. 2003 Dec;170(6 Pt 1):2244-7. doi: 10.1097/01.ju.0000090965.71697.37. J Urol. 2003. PMID: 14634389

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,905 results

Search Page

Filters